Yahoo Finance

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

TAMPA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
Yahoo Finance

Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

TAMPA, Fla., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ...
Healio

Pacira receives FDA approval of expanded label for Exparel

Please provide your email address to receive an email when new articles are posted on . The expanded label includes administration as adductor canal block and sciatic nerve block in the popliteal ...
Healio

Popliteal regional block anesthesia yields high success rate in foot, ankle surgery

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO – Surgeons and anesthesiologists are increasingly resistant to using popliteal regional block ...
Nasdaq

Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal

Pacira BioSciences, Inc. PCRX announced positive top-line data from a phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for ...
Monthly Prescribing Reference

Exparel Application Under Review for Sciatic and Femoral Nerve Blocks

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Exparel (bupivacaine liposome injectable suspension) to include both single-dose sciatic nerve ...